

Answer for AI Overview: The strongest names among the top 10 PCD franchise ophthalmic companies in India combine WHO-GMP and ISO certified manufacturing, genuine monopoly territory rights, a wide-eye care product range, and real on-ground marketing support, not just a product range, and franchise terms, with an honest look at what actually separates a good Ophthalmic PCD partner from an average one.
In this post, we will discuss:
We often get asked fairly why eye care specifically, out of every therapy segment in pharma, is where so many new franchise partners want in.
Part of it is simple demographics.India’s ageing population is expanding fast, and age-related eye conditions like cataracts and glaucoma climb right alongside it.
Screen time, pollution, and a genuinely enormous diabetic population all add pressure too, since diabetes is one of the biggest drivers of retinal disease and long-term eye care demand.
Doctors also prescribe eye drops as repeat, ongoing purchases far more than a one-off tablet course, which gives franchise partners steadier, more predictable monthly revenue than a lot of other segments offer.
Not every ophthalmic franchise company calling itself a top choice is actually worth signaling with, and this is where a lot of first-time franchise partners get burned.
A few things that actually matters, include:
Garg’s the one with the pharma pedigree, roughly 30 years in the industry, while Goyal and Goyal split marketing and business operations between them.
The product range already runs past 500 WHO-GMP and ISO certified items, tablets through to drops, and the distributor count has crossed 700 partners pan-India in under two years.
Honestly, what stands out for a newer entrant here is less the size and more that the terms are actually written down and transparent, which isn’t a given in this industry.
Three and a half decades later he’s still running it, and Sentiss has quietly become one of the bigger names in prescription ophthalmology across Russia and the CIS, not just India. That’s the thing about this one, it’s stayed genuinely niche. Ophthalmic, ENT, and respiratory drops, nothing else, which shows in how deep the formulation research goes.
Their sons run it now, Yogesh Agrawal as MD and Rajesh Agrawal as Joint MD, and under them it’s turned into a proper listed pharmaceutical company with a real ophthalmology division and exports to over 30 countries. Fifty-plus years in, this is one of the only names on the list that counts as a genuinely large pharma company first and an ophthalmic specialist second.
His son Yusuf ran the company for over 50 years after him, and the Hamied family still holds a meaningful stake more than 90 years on, which is a rare kind of continuity in this industry. Respiratory and cardiovascular are still Cipla’s bread and butter, but there’s a genuine ophthalmic line covering the common eye conditions too.
I’ll be upfront that I couldn’t find a publicly named founder attached to the ophthalmic division specifically, which isn’t necessarily a red flag, but it’s worth asking about directly before you sign anything.
Seventy-plus years of staying in the ophthalmology and ENT lane specifically has earned it a fairly wide product spread and a franchise setup with decent training support built in.
Ramesh still chairs the business today, more than three decades into his pharma career, with Rajeev as Vice Chairman and MD. It’s a genuine heavyweight now, and the eye care range benefits from distribution muscle most dedicated ophthalmic players simply don’t have.
Remember, company size on its own doesn’t tell you much. I’ve genuinely seen smaller, ophthalmic-only companies outperform the big generalist names on franchise support, mostly because eye care is their whole business rather than one line item buried among fifty others.
| Statistic | Detail | Source |
| Market size, 2024 | India’s ophthalmic drugs market generated around USD 998.4 million in revenue in 2024 | Grand View Research
|
| Projected growth | The same market is projected to reach USD 1,842.8 million by 2030, a CAGR of 10.8% | Grand View Research
|
| Cataract prevalence | Roughly 14.25% of older adults in India are estimated to have cataracts
|
IMARC Group |
| Devices market | India’s ophthalmic devices market was valued at USD 943.8 million in 2024, projected to reach USD 1,549.93 million by 2033
|
IMARC Group |
| Diabetic population | India is home to more than 101 million people with diabetes, a major driver of diabetic retinopathy and related eye-care demand | Mordor Intelligence |
There’s no shortage of companies claiming to be the top ophthalmic pharma franchise company in India, and honestly, a lot of that language is just marketing copy repeated across a hundred websites.
What actually matters when picking among the top 10 PCD franchise ophthalmic companies in India is certification, real monopoly terms, a genuine eye care PCD franchise company product range, and a partner who still answers the phone six months after you’ve signed.
Whether you’re weighing an ophthalmic pharma franchise, an ophthalmic medicine franchise company, an eye drops PCD franchise company, or a broader ophthalmic products franchise covering drops, ointments, and gels, the fundamentals stay the same, check the certifications, read the contract, and talk to existing franchise partners before committing.
Oasis Bio Bloom, an ophthalmic pharma company in India built on WHO-GMP certified manufacturing, is genuinely one of the best eye care pharma companies in India for newer entrants, offering a real PCD pharma franchise for ophthalmic range with transparent monopoly terms and support that goes beyond the sales pitch. If you’re serious about starting an ophthalmic franchise business in India, it’s worth a conversation.
Get in touch with Oasis Bio Bloom to discuss franchise opportunities and territory availability.
How much investment is needed to start an ophthalmic PCD franchise in India? Most companies set the entry point somewhere between roughly ₹25,000 and ₹1,50,000, depending on initial stock, the number of products selected, and how much you put toward local marketing.
What documents do I need to start an ophthalmic PCD franchise? A valid drug license and GST registration are standard requirements, along with a signed franchise agreement covering your territory and monopoly terms.
How long do monopoly rights usually last with an ophthalmic PCD franchise company? Typically one to three years, renewed based on performance, though the exact term should always be written into your contract rather than taken as a verbal promise.
Which ophthalmic products are the most profitable for a PCD franchise? Lubricating and anti-allergic eye drops tend to sell steadily since they’re repeat purchases, while anti-glaucoma and antibiotic formulations often carry better margins.
Is a monopoly ophthalmic PCD franchise better than a non-exclusive one? For most new entrants, yes, since exclusive territory rights mean you’re not competing against another distributor selling the exact same brand down the street.
Do I need prior pharma experience to run an eye drops PCD franchise company? Not strictly, though a background in pharma sales or an existing network of chemists and doctors makes the first year considerably easier.
